Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tcm Cells Immunotherapy in Recurrent Stage II NSCLC
NCT03432156Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC), sponsored by Beijing Friendship Hospital. Primary endpoint: Progression-free Survival at 12 weeks. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03432156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432156.